Related resources
Search for item elsewhere
University researcher(s)
Academic department(s)
BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor.
Pierce A, Spooncer E, Ainsworth S, Whetton A
Oncogene. 2002;21( 19).
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
Chronic myeloid leukaemia (CML), a hematopoietic stem cell disorder is characterized by the expression of BCR-ABL. To investigate the effects of BCR-ABL on multipotent hematopoietic cells, a temperature sensitive BCR-ABL tyrosine kinase was expressed in the cell line, FDCP-Mix. BCR-ABL mediated an increase in c-kit expression that correlated with an enhanced mitogenic response to SCF. This was not observed in the absence of Bcr-Abl kinase activity or presence of the BCR-ABL inhibitor STI571, which also inhibits c-kit. When cultured in a combination of SCF plus G-CSF the FDCP-Mix cells undergo neutrophilic differentiation over a 7-10 day period. When BCR-ABL was active there was a marked inhibition of cell maturation compared to control cells in which BCR-ABL was either inactive or not present. However, BCR-ABL did not block differentiation as the cells eventually undergo terminal maturation. These data argue that BCR-ABL is directly responsible for the enhanced response to SCF reported in CML progenitor cells. Furthermore, although the primary effect of STI571 is via direct inhibition of BCR-ABL, STI571 additionally reduces the enhanced response to SCF. Thus there are two sites of STI571 action of potential importance in Bcr-Abl expressing cells.
Keyword(s)
Humans; Research Support, Non-U.S. Gov't; Up-Regulation; antagonists & inhibitors: Fusion Proteins, bcr-abl; biosynthesis: Proto-Oncogene Protein c-kit; cytology: Neutrophils; drug effects: Cell Differentiation; drug effects: Cell Division; drug effects: Cell Line; drug effects: Hematopoietic Stem Cells; pharmacology: Antineoplastic Agents; pharmacology: Enzyme Inhibitors; pharmacology: Granulocyte Colony-Stimulating Factor; pharmacology: Piperazines; pharmacology: Pyrimidines; pharmacology: Stem Cell Factor